

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st DECEMBER 2020

Rs. in Lakhs unless otherwise stated

Sl. No.	PARTICULARS	STANDALONE					
		Quarter Ended			Nine Months ended		Year ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
	Un-Audited	Un-Audited	Audited	Un-Audited	Audited	Audited	
1	Income						
	Revenue from operations	27,493.32	23,738.81	17,870.62	75,055.37	64,902.52	83,378.97
	Other Income	484.29	35.68	488.75	1,093.88	1,277.73	1,811.73
	Total income	27,977.61	23,774.49	18,359.37	76,149.25	66,180.25	85,190.70
2	Expenses						
	a) Cost of materials consumed	7,975.82	7,717.95	5,686.20	22,294.04	17,600.14	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,354.57)	(355.65)	(1,303.88)	(1,235.58)	21.80	(1,105.44)
	d) Employee benefits expense	2,134.71	2,092.90	1,542.08	5,972.03	4,772.74	6,510.44
	e) R & D expense	265.85	381.42	269.15	955.12	1,072.36	1,413.14
	f) Finance costs	273.15	326.29	717.56	920.06	1,460.89	2,181.26
	g) Depreciation and amortisation expense	875.75	750.02	551.12	2,332.11	1,654.30	2,350.69
	h) Manufacturing Expense	3,551.28	2,970.64	2,722.77	8,910.63	7,864.09	10,384.42
	i) Other Expenses	1,104.68	1,082.22	997.17	3,283.51	2,818.87	3,672.81
	Total expenses	14,826.67	14,965.79	11,182.17	43,431.92	37,265.19	49,431.67
3	Profit before exceptional items & Tax	13,150.94	8,808.70	7,177.20	32,717.33	28,915.06	35,759.03
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax	13,150.94	8,808.70	7,177.20	32,717.33	28,915.06	35,759.03
6	Tax Expenses						
	a) Current tax	3,444.22	2,163.92	1,962.27	8,336.86	7,531.87	8,880.94
	b) Deferred tax	(56.76)	111.78	15.08	(39.01)	(300.76)	(129.93)
7	Net Profit/ (Loss) for the period/year	9,763.48	6,533.00	5,199.85	24,419.48	21,683.95	27,008.02
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(27.33)	(27.32)	(82.35)	(81.98)	(90.81)	(109.31)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.87	6.88	19.90	20.63	22.86	27.51
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.46)	(20.44)	(62.45)	(61.35)	(67.95)	(81.80)
9	Total Comprehensive Income for the period (7+8)	9,743.02	6,512.56	5,137.40	24,358.13	21,616.00	26,926.22
10	Paid-up equity share capital (Face Value of the Share Re.1/- each)	2,545.65	2,545.65	1,272.82	2,545.65	1,272.82	1,272.82
11	Other Equity	-	-	-	-	-	77,010.16
12	Earning Per Share (EPS)-Restated, ref note No: 4 (Face value of Rs.1/- each)						
	a) Basic	3.84	2.57	2.04	9.59	8.52	10.61
	b) Diluted	3.84	2.57	2.04	9.59	8.52	10.61
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

		CONSOLIDATED					
Sl. No.	PARTICULARS	Quarter Ended			Nine Months ended		Year ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
		Un-Audited	Un-Audited	Audited	Un-Audited	Audited	Audited
1	Income						
	Revenue from operations	27,493.32	23,738.81	17,870.62	75,055.37	64,902.52	83,378.97
	Other Income	484.29	35.68	488.75	1,093.88	1,277.73	1,811.73
	Total income	27,977.61	23,774.49	18,359.37	76,149.25	66,180.25	85,190.70
2	Expenses						
	a) Cost of materials consumed	7,975.82	7,717.95	5,686.20	22,294.04	17,600.14	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,354.57)	(355.65)	(1,303.88)	(1,235.58)	21.80	(1,105.45)
	d) Employee benefits expense	2,134.71	2,092.90	1,542.08	5,972.03	4,772.74	6,510.44
	e) R & D expense	265.85	381.42	269.15	955.12	1,072.36	1,413.15
	e) Finance costs	273.15	326.29	760.55	920.06	1,584.85	2,306.60
	f) Depreciation and amortisation expense	875.75	750.02	551.12	2,332.11	1,654.30	2,350.69
	g) Manufacturing Expenses	3,551.28	2,970.64	2,722.77	8,910.63	7,864.09	10,384.42
	h) Other Expenses	1,105.61	1,082.58	998.57	3,287.40	2,821.30	3,676.58
	Total expenses	14,827.60	14,966.15	11,226.56	43,435.81	37,391.58	49,560.78
3	Profit before exceptional items, Tax & share in profit/(Loss) of Associates	13,150.01	8,808.34	7,132.81	32,713.44	28,788.67	35,629.92
4	Add : Share of profit/(Loss) of Associates	1,599.98	875.26	635.58	3,507.00	2,724.38	4,821.26
5	Profit before exceptional items, Tax	14,749.99	9,683.60	7,768.39	36,220.44	31,513.05	40,451.18
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax	14,749.99	9,683.60	7,768.39	36,220.44	31,513.05	40,451.18
8	Tax Expenses						
	a) Current tax	3,444.22	2,163.92	1,962.27	8,336.86	7,531.87	8,880.94
	b) Deferred tax	(56.76)	111.78	15.08	(39.01)	(300.76)	(129.93)
9	Net Profit/ (Loss) for the period/year	11,362.53	7,407.90	5,791.04	27,922.59	24,281.94	31,700.17
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(27.33)	(27.32)	(82.35)	(81.98)	(90.81)	(109.30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.87	6.88	19.90	20.63	22.86	27.51
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.46)	(20.44)	(62.45)	(61.35)	(67.95)	(81.79)
11	Total Comprehensive Income for the period	11,342.07	7,387.46	5,728.59	27,861.24	24,213.99	31,618.38
12	Paid-up equity share capital (Face Value of the Share Re.1.00)	2,545.65	2,545.65	1,272.82	2,545.65	1,272.82	1,272.82
13	Other Equity	-	-	-	-	-	83,203.45
14	Earning Per Share (EPS)-Restated, ref note No: 4 (Face value of Rs.1/- each)						
	a) Basic	4.46	2.91	2.27	10.97	9.54	12.45
	b) Diluted	4.46	2.91	2.27	10.97	9.54	12.45
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

Notes:

- 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 10th February, 2021. The above results have been subjected to limited review by the statutory auditors of the company
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc. and Associate Rising Pharma Holdings, Inc.
- 4) The Board has allotted the Bonus shares at 1:1 ratio in it's Board meeting held on 29th September, 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paid-up share capital on account of Bonus issue of Rs.1272.82 Lakhs has been appropriated from share premium account.
- 5) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 6) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06, 2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Suven Life Sciences Limited (SLSL) to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.
- 7) The COVID-19 did not have a major impact on the business and research operations, which includes our subsidiary, Suven Pharma, Inc.
- 8) Pursuant to a fire accident on 26th, April 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended 31st December 2020, the company has written off net book value of assets aggregating Rs 128.80 Lakhs and recognised a minimum insurance claim receivable for equivalent amount.
- 9) The Board has declared in its meeting held on 10th February 2021 an Interim Dividend of Rs.1.00 per equity share (100% of face value of Rs.1.00/- each) for the financial year 2020-21.
- 10) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

VENKAT JASTI
Chairman & MD
DIN: 00278028

Place: Hyderabad
Date: 10th February, 2021